sertindole (Serdolect)

01/01/2000 - "Sertindole is effective against positive and negative symptoms of schizophrenia within the dose range 12-24 mg daily, with an optimal starting dose of 16 mg daily. "
01/01/2004 - "In pivotal clinical trials, sertindole has demonstrated significantly greater efficacy than placebo against both the positive and negative symptoms of schizophrenia. "
11/01/1997 - "Based on these findings, sertindole appears to be an effective antipsychotic agent for the treatment of positive and negative symptoms of schizophrenia, with efficacy that is clearly superior to placebo. "
01/01/2006 - "Sertindole improves negative symptoms, and is also effective for the treatment of neuroleptic-resistant schizophrenia. "
01/01/2006 - "Sertindole is a non-sedating atypical antipsychotic effective in the management of schizophrenia and is associated with placebo-level incidence of extrapyramidal symptoms (EPS). "

11/01/1997 - "Sertindole should prove to be a very useful addition to the therapeutic options available for the treatment of psychotic disorders."
01/01/2005 - "Clinical observations of sertindole in 53 hospitalised patients with psychotic disorders."
07/01/2000 - "We report drug surveillance data in 34 comorbid and comedicated sertindole treated patients suffering from different psychotic disorders. "
11/01/1998 - "[Management of schizophrenic psychoses: a one-year experience with Serdolect]."
09/01/1997 - "Sertindole appears to be a useful treatment in psychotic disorders. "

11/01/2005 - "However, the beneficial effect of sertindole on severe, late-occurring movement disorders, as observed in four difficult-to-treat patients, appears to be promising."
11/01/2005 - "Three of the four patients apparently recovered from the movement disorders after switching to sertindole. "
10/01/2009 - "Sertindole, a 2nd generation antipsychotic with low movement disorder side effects, was compared with haloperidol in a 6-week crossover study. "
01/01/2009 - "Sertindole may induce fewer movement disorders, but more cardiac effects, weight change and male sexual dysfunction than risperidone. "
01/01/2005 - "There were no statistically significant differences found between sertindole and placebo for the movement disorders akathisia, cogwheel rigidity, hypertonia and tremor or somnolence. "

11/01/2010 - "We report the case of a 46-year-old patient with schizophrenia who developed a rebound insomnia confirmed by polysomnography after discontinuation of long-term treatment with clozapine and changing to sertindole therapy. "
11/01/2010 - "Combined treatment with quetiapine and sertindole in therapy refractory insomnia after clozapine discontinuation."
11/01/2010 - "In conclusion, the combination of sertindole and quetiapine might be a safe and effective combination in therapy-refractory insomnia after clozapine discontinuation in schizophrenia."

09/01/2014 - "The reviewed studies suggest a beneficial effect of sertindole on positive, negative and cognitive symptoms, and on relapse prevention. "
11/01/2012 - "Sertindole's pharmacological profile, pharmacokinetics, neuophysiological properties, efficacy on positive, negative and cognitive symptoms and safety issues are covered in this article, based on a literature review from 1990 to 2012. "
06/01/2015 - "Regarding its efficacy on cognitive symptoms, sertindole effect is supported by both preclinical and clinical studies versus haloperidol and olanzapine; however, its role on cognition needs further clarification. "